Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration.

J Infect Dis. 2000 Apr;181(4):1304-12. Unique Identifier : AIDSLINE MED/20227752
Johnson JL; Kamya RM; Okwera A; Loughlin AM; Nyole S; Hom DL; Wallis RS; Hirsch CS; Wolski K; Foulds J; Mugerwa RD; Ellner JJ; Department of Medicine, Division of Infectious Diseases, Case; Western Reserve University, Tuberculosis Research Unit,; Cleveland, OH 44106-4984, USA. jlj@po.cwru.edu

Abstract: Adjunctive immunotherapy with heat-killed Mycobacterium vaccae was studied in a randomized, placebo-controlled trial of 120 non-human immunodeficiency virus-infected adults with newly diagnosed pulmonary tuberculosis. Patients were randomized to a single dose of M. vaccae or placebo 1 week after beginning chemotherapy and were followed up for 1 year. M. vaccae was safe and well tolerated. The rate of sputum culture conversion after 1 month of tuberculosis treatment was 35% in the M. vaccae group and only 14% in the placebo group (P=.01) but was comparable at 2 months and thereafter. Patients receiving M. vaccae had greater improvement on chest radiography at 6 months (91% vs. 77% for placebo recipients; P=.04) and 12 months (94% vs. 80%; P=.04) after initiation of tuberculosis treatment. These data provide evidence of an early increase in sputum culture conversion and greater radiographic improvement among patients who received M. vaccae. Further studies are warranted.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL Adult Female Health Status Indicators Human Male Mycobacterium/CLASSIFICATION/*IMMUNOLOGY Radiography, Thoracic Sputum/MICROBIOLOGY Support, U.S. Gov't, P.H.S. Tuberculosis, Pulmonary/*THERAPY Uganda Vaccines, Inactivated

KWDclinicaltrialjournalarticlerandomizedcontrolledtrialadultfemalehealthstatusindicatorshumanmalemycobacterium/classification/KWDimmunologyradiography,thoracicsputum/microbiologysupport,uKWDsKWDgov't,pKWDhKWDsKWDtuberculosis,pulmonary/KWDtherapyugandavaccines,inactivated
000830
A0080953

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .